Dexclamol

Dexclamol

Clinical data
Other names	AY 24169
Identifiers
IUPAC name (1R,6R,8R)-6-propan-2-yl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
CAS Number	52340-25-7 HCl: 52389-27-2
PubChem CID	91267
ChemSpider	16736937
UNII	IGL2M625XH
ChEMBL	ChEMBL320656
CompTox Dashboard (EPA)	DTXSID001023746
Chemical and physical data
Formula	C24H29NO
Molar mass	347.502 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O
InChI InChI=1S/C24H29NO/c1-16(2)24(26)12-13-25-15-21-19-8-4-3-6-17(19)10-11-18-7-5-9-20(23(18)21)22(25)14-24/h3-9,16,21-22,26H,10-15H2,1-2H3/t21-,22-,24-/m1/s1 Key:UPMOVJBGNREKJV-CQOQZXRMSA-N

Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic. ^{[1] [2] [3] [4]} It acts as a dopamine receptor antagonist. ^[1]

See also

• Butaclamol

References

1. Humber LG, Bruderlein FT, Voith K (November 1975). "Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor". Molecular Pharmacology. 11 (6): 833–840. PMID   1239657.
2. Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Springer US. doi:10.1007/978-1-4757-2085-3. ISBN   978-1-4757-2087-7.
3. Castañer J, Paton DM (1976). "Dexclamol hydrochloride". Drugs of the Future. 1 (8): 366. doi:10.1358/dof.1976.001.08.1002521.
4. US 3657250,Bruderlein FT, Humber LG,"Benzocycloheptaisoquinoline derivatives", assigned to Ayerst Mckenna and Harrison Inc.